The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design

Conclusions
HCV T cell specificity is distinct between genotypes with limited T cell cross-reactivity in resolved and chronic disease. Therefore, viral regions targeted in natural HCV infection may not serve as attractive targets for a vaccine that aims to protect against multiple HCV genotypes.

Source: Gut - December 8, 2015 Category: Gastroenterology Authors: von Delft, A., Humphreys, I. S., Brown, A., Pfafferott, K., Lucas, M., Klenerman, P., Lauer, G. M., Cox, A. L., Gaudieri, S., Barnes, E. Tags: Open access Hepatology Source Type: research